Exact Sciences Corporation [NASDAQ: EXAS] plunged by -$1.05 during the normal trading session on Wednesday and reaching a high of $64.31 during the day while it closed the day at $64.25. The company report on January 8, 2023 that Exact Sciences Announces Preliminary Fourth Quarter 2022 Results.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Preliminary fourth quarter highlights:.
Expected total fourth quarter revenue, excluding COVID-19 testing, increased 28% compared to the fourth quarter 2021, with Screening revenue of $401.8-$402.8 million and Precision Oncology revenue of $142.9-$143.9 million.
Exact Sciences Corporation stock has also loss -5.40% of its value over the past 7 days. However, EXAS stock has inclined by 104.68% in the 3 months of the year. Over the past six months meanwhile, it has gained 42.43% and gained 29.77% year-on date.
The market cap for EXAS stock reached $11.07 billion, with 177.00 million shares outstanding and 176.12 million shares in the current float. Compared to the average trading volume of 2.70M shares, EXAS reached a trading volume of 3145156 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Exact Sciences Corporation [EXAS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EXAS shares is $63.39 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EXAS stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Raymond James have made an estimate for Exact Sciences Corporation shares, keeping their opinion on the stock as Mkt Perform, with their previous recommendation back on January 18, 2023. While these analysts kept the previous recommendation, Craig Hallum dropped their target price from $60 to $35. The new note on the price target was released on October 19, 2022, representing the official price target for Exact Sciences Corporation stock. Previously, the target price had yet another raise to $55, while Credit Suisse analysts kept a Outperform rating on EXAS stock.
The Average True Range (ATR) for Exact Sciences Corporation is set at 3.42, with the Price to Sales ratio for EXAS stock in the period of the last 12 months amounting to 5.52. The Price to Book ratio for the last quarter was 3.66, with the Price to Cash per share for the same quarter was set at 3.88.
EXAS stock trade performance evaluation
Exact Sciences Corporation [EXAS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -5.40. With this latest performance, EXAS shares gained by 20.88% in over the last four-week period, additionally plugging by 42.43% over the last 6 months – not to mention a drop of -13.94% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EXAS stock in for the last two-week period is set at 62.76, with the RSI for the last a single of trading hit 58.24, and the three-weeks RSI is set at 64.04 for Exact Sciences Corporation [EXAS]. The present Moving Average for the last 50 days of trading for this stock 51.09, while it was recorded at 66.36 for the last single week of trading, and 45.76 for the last 200 days.
Exact Sciences Corporation [EXAS]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Exact Sciences Corporation [EXAS] shares currently have an operating margin of -41.27 and a Gross Margin at +68.66. Exact Sciences Corporation’s Net Margin is presently recorded at -33.71.
Return on Equity for this stock declined to -19.18, with Return on Assets sitting at -9.56.
Exact Sciences Corporation’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.20 and a Current Ratio set at 2.50.
Exact Sciences Corporation [EXAS]: Insider Ownership positions
There are presently around $10,288 million, or 89.30% of EXAS stock, in the hands of institutional investors. The top three institutional holders of EXAS stocks are: VANGUARD GROUP INC with ownership of 16,676,611, which is approximately 4.373% of the company’s market cap and around 0.70% of the total institutional ownership; ARK INVESTMENT MANAGEMENT LLC, holding 16,040,490 shares of the stock with an approximate value of $1.03 billion in EXAS stocks shares; and WELLINGTON MANAGEMENT GROUP LLP, currently with $721.38 million in EXAS stock with ownership of nearly 11.344% of the company’s market capitalization.
Positions in Exact Sciences Corporation stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 247 institutional holders increased their position in Exact Sciences Corporation [NASDAQ:EXAS] by around 20,190,630 shares. Additionally, 214 investors decreased positions by around 23,750,687 shares, while 94 investors held positions by with 116,184,567 shares. The mentioned changes placed institutional holdings at 160,125,884 shares, according to the latest SEC report filing. EXAS stock had 68 new institutional investments in for a total of 10,213,887 shares, while 74 institutional investors sold positions of 3,981,892 shares during the same period.